To determine the effect of the modified SQV/r (saquinavir boosted by ritonavir) regimen (500/100 mg for the 1st week followed by 1000/100 mg for the 2nd week) on the QTc interval, pharmacokinetics, and antiviral activity in treatmentnaïve HIV1 infected patients

Trial Profile

To determine the effect of the modified SQV/r (saquinavir boosted by ritonavir) regimen (500/100 mg for the 1st week followed by 1000/100 mg for the 2nd week) on the QTc interval, pharmacokinetics, and antiviral activity in treatmentnaïve HIV1 infected patients

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Ritonavir (Primary) ; Saquinavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 13 Jun 2012 Planned number of patients changed from 24 to 20 as reported by United Kingdom Clinical Research Network.
    • 05 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top